CA2259603A1 - Use of polymeric compositions for reducing or eliminating post-surgical adhesion formation - Google Patents

Use of polymeric compositions for reducing or eliminating post-surgical adhesion formation

Info

Publication number
CA2259603A1
CA2259603A1 CA002259603A CA2259603A CA2259603A1 CA 2259603 A1 CA2259603 A1 CA 2259603A1 CA 002259603 A CA002259603 A CA 002259603A CA 2259603 A CA2259603 A CA 2259603A CA 2259603 A1 CA2259603 A1 CA 2259603A1
Authority
CA
Canada
Prior art keywords
group
poly
acid
ethylene oxide
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA002259603A
Other languages
French (fr)
Other versions
CA2259603C (en
Inventor
Daniel Cohn
Eli Pines
Anna Hotovely
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Life Medical Sciences Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2259603A1 publication Critical patent/CA2259603A1/en
Application granted granted Critical
Publication of CA2259603C publication Critical patent/CA2259603C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C08ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08GMACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G69/00Macromolecular compounds obtained by reactions forming a carboxylic amide link in the main chain of the macromolecule
    • C08G69/44Polyester-amides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/74Synthetic polymeric materials
    • A61K31/765Polymers containing oxygen
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/74Synthetic polymeric materials
    • A61K31/765Polymers containing oxygen
    • A61K31/77Polymers containing oxygen of oxiranes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/74Synthetic polymeric materials
    • A61K31/785Polymers containing nitrogen
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61LMETHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L31/00Materials for other surgical articles, e.g. stents, stent-grafts, shunts, surgical drapes, guide wires, materials for adhesion prevention, occluding devices, surgical gloves, tissue fixation devices
    • A61L31/04Macromolecular materials
    • A61L31/06Macromolecular materials obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C08ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08GMACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G63/00Macromolecular compounds obtained by reactions forming a carboxylic ester link in the main chain of the macromolecule
    • C08G63/02Polyesters derived from hydroxycarboxylic acids or from polycarboxylic acids and polyhydroxy compounds
    • C08G63/06Polyesters derived from hydroxycarboxylic acids or from polycarboxylic acids and polyhydroxy compounds derived from hydroxycarboxylic acids
    • C08G63/08Lactones or lactides
    • CCHEMISTRY; METALLURGY
    • C08ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08GMACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G63/00Macromolecular compounds obtained by reactions forming a carboxylic ester link in the main chain of the macromolecule
    • C08G63/66Polyesters containing oxygen in the form of ether groups
    • C08G63/664Polyesters containing oxygen in the form of ether groups derived from hydroxy carboxylic acids

Abstract

The present invention relates to a method for reducing adhesions associated with post-operative surgery. The present method comprises administering or affixing a polymeric composition preferably comprising chain extended, coupled or crosslinked polyester/poly(oxyalkylene) ABA triblocks or AB diblocks having favourable EO/LA ratios to a site in the body which has been subjected to trauma, e.g. by surgery, excision or inflammatory disease. In the present invention, the polymeric material provides a barrier to prevent or reduce the extent of adhesions forming.

Claims (92)

1. A method for reducing or preventing adhesions in a patient comprising exposing tissue which has been subjected to tissue damage and is at risk for the formation of adhesions to a prepolymerized polymeric composition comprising chain extended, coupled or crosslinked poly(ester)/poly(oxyalkylene) ABA triblocks or AB diblocks, where A is a polyester unit and B is a polyoxyalkylene polymer unit, said polymeric composition having an EO/LA ratio falling within the range of about 0.1 to about 100.
2. The method according to claim 1 wherein said polyester unit is derived from the polymerization of monomers selected from the group consisting of lactic acid, lactide, glycolic acid, glycolide, .beta.-propiolactone, .epsilon.-caprolactone, .delta.-glutarolactone, .delta.-valerolactone, .beta.-butyrolactone, pivalolactone, .alpha.,.alpha.-diethylpropiolactone, ethylene carbonate, trimethylene carbonate, .gamma.-butyrolactone, p-dioxanone, 1,4-dioxepan-2-one, 3-methyl-1,4-dioxane-2,5-dione,
3,3,-dimethyl-1-4-dioxane-2,5-dione, cyclic esters of .alpha.-hydroxybutyric acid, .alpha.-hydroxyvaleric acid, .alpha.-hydroxyisovaleric acid, .alpha.-hydroxycaproic acid, .alpha.-hydroxy-.alpha.-ethylbutyric acid, .alpha.-hydroxyisocaproic acid, .alpha.-hydroxy-.alpha.-methyl valeric acid, .alpha.-hydroxyheptanoic acid, .alpha.-hydroxystearic acid, .alpha.-hydroxylignoceric acid, salicylic acid and mixtures, thereof.

3. The method according to claim 1 wherein said polyester comprises poly(aliphatic hydroxy carboxylic acid).
4. The method according to claim 1 wherein said polyester comprises poly(aliphatic .alpha.-hydroxy carboxylic acid).
5. The method according to claim 1 wherein said polyester is obtained from polymerization of an aliphatic hydroxycarboxylic acid or ester selected from the group consisting of L-lactic acid, D,L-lactic acid, glycolic acid, L-lactide, D,L-lactide, glycolide or mixtures thereof.
6. The method according to claim 1 wherein said poly(oxyalkylene) polymer is comprised of poly(ethylene oxide).
7. The method according to claim 1 wherein said poly(oxyalkylene) polymer is comprised of a poly(ethylene oxide) homopolymer or poly(ethylene oxide)-co-poly(propylene oxide) block copolymer.
8. The method according to claim 1 wherein said polyester comprises units of an aliphatic hydroxycarboxylic acid or the corresponding cyclic dimeric ester selected from the group consisting of L-lactic acid, D,L-lactic acid, glycolic acid, L-lactide, D,L-lactide, glycolide or mixtures and said poly(oxyalkylene) polymer is comprised of a poly(ethylene oxide) homopolymer or poly(ethylene oxide)-co-poly(propylene oxide) block copolymers.
9. The method according to claim 5 wherein said A block is between about 1 and 400 carboxylic acid units in size and said B block is varies in size from about 100 Da to about 200,000 Da.
10. The method according to claim 7 wherein said A block comprises carboxylic acid units derived from L-lactide or D,L-lactide and said B block is comprised of poly(ethylene oxide).
11. The method according to claim 7 wherein said A block is approximately 6 to 30 carboxylic acid units in length and said B block is comprised of poly(ethylene oxide) having a molecular weight of between about 1,500 and 10,000 Da.
12. The method according to claim 1 wherein said composition is in the form of apreformed structure such as a film, rod, tube, bead, foam or ring or a dispersion, suspension, gel, liquid, spray or viscous solution.
13. The method according to claim 1 wherein said composition further includes a bioactive agent.
14. The method according to claim 1 wherein said composition is chain extended or coupled with a diisocyanate of the general formula:

where R' is a C2 to C12 alkylene group, a cycloalkyl or cycloalkyl-containing group, an aryl or aryl-containing group, 4,4'-diphenylmethane, toluene, naphthalene, 4,4'-dieyelohexylmethane, eyelohexyl, 3,3'-dimethylphenyl, 3,3'-dimethyl-diphenylmethane, 4,6'-xylylene, 3,5,5-trimethylcyclohexyl, 2,2,4-trimethylhexamethylene, p-phenylene or a poly(ethylene oxide) containing or poly(ethylene oxide) rich chain.
15. The method according to claim 1 wherein said composition is chain extended or coupled with a compound of the general formula:

where R'' is a C0 to C12 alkylene group or a hydroxyl or carboxylic acid substituted alkylene group, alkene, a cycloalkyl, hydroxyl or carboxylic acid containing cycloalkyl or cycloalkyl-containing group, an aryl or aryl-containing group or a polyoxyalkylene chain-containing group comprised of poly(ethylene oxide), poly(ethylene oxide)-co-poly(propylene oxide) or poly(ethylene oxide) rich ehains and L is hydroxyl, a halide selected from Cl, I or Br or an ester group.
16. The method according to claim 15 wherein said poly(oxyalkylene) comprises poly(ethylene oxide).
17. The method according to claim 14 wherein said poly(oxyalkylene) comprises poly(ethylene oxide).
18. The method according to claim 1 wherein said composition comprises AB diblocks.
19. The method according to claim 18 wherein said AB diblock is end-capped with a non-reactive group.
20. The method according to claim 19 wherein said unreactive group is selected from the group consisting of alkyl, aryl, aralkyl, a substituted alkyl, aryl, aralkyl and a protecting group.
21. The method according to claim 1 wherein said composition comprises ABA triblocks.
22. The method according to claim 1 wherein said composition is crosslinked.
23. The method according to claim 2 wherein said composition is crosslinked.
24. A method for reducing or preventing adhesions in a patient comprising exposing tissue which has been subjected to tissue damage and is at risk for the formation of adhesions to a polymeric composition comprising polymers of the chemical structure:

where m, a and b are positive integers, R is an ethylene group and/or propylene group with the proviso that R is not exclusively a propylene group when R' contains an absence of poly(ethylene oxide), R' is a C2 to C12 alkylene group, a cycloalkyl or cycloalkyl-containing group, an aryl or aryl-containing group, 4,4'-diphenylmethane, toluene, naphthalene, 4,4'-dicyclohexylmethane, cyclohexyl, 3,3'-dimethylphenyl, 3,3'-dimethyl-diphenylmethane, 4,6'-xylylene, 3,5,5-trimethylcyclohexyl, 2,2,4-trimethylhexamethylene, p-phenylene, or a poly(ethylene oxide) containing or poly(ethylene oxide) rich chain and R1 is H or CH3.
25. The method according to claim 24 wherein R1 is CH3.
26. The method according to claim 24 wherein m is 4 to about 5,000, R1 is CH3 and R is an ethylene group.
27. The method according to claim 24 wherein m is about 30 to about 230, R1 is CH3 and R is an ethylene group.
28. The method according to claim 24 wherein R' is a C6 alkylene group.
29. The method according to claim 24 wherein said composition is in the form of a preformed structure such as a film, rod, tube, bead, foam, ring or a viscous liquid, dispersion, suspension, viscous solution, spray or gel.
30. The method according to claim 24 wherein a and b are the same integer.
31. The method according to claim 24 wherein said polymeric composition includes a bioactive agent.
32. The method according to claim 24 wherein said poly(oxyalkylene) is poly(ethylene oxide).
33. A method for reducing or preventing adhesions in a patient comprising exposing tissue which has been subjected to tissue damage and is at risk for the formation of adhesions to a polymeric composition comprising polymers of the chemical structure:

where m, x and y are positive integers, R is an ethylene or propylene group with the proviso that R is not exclusively a propylene group when R'' contains an absence of poly(ethylene oxide), R1 is a hydrogen or methyl group, R'' is a C 0 to C12 alkylene group or a hydroxyl or carboxylic acid substituted alkyl group, a cycloalkyl, a hydroxyl-containing cycloalkyl, or cycloalkyl-containing group, an aryl or aryl-containing group, or a polyoxyalkylene chain-containing group comprised of poly(ethylene oxide), poly(ethylene oxide)-co-poly(propylene oxide) or a poly(ethylene oxide) rich chain.
34. The method according to claim 33 wherein R1 is CH3.
35. The method according to claim 33 wherein m is 4 to about 5,000, R1 is CH3 and R is an ethylene group.
36. The method according to claim 33 wherein m is about 30 to about 230, R1 is CH3 and R is an ethylene group.
37. The method according to claim 33 wherein R' is a C6 alkylene group.
38. The method according to claim 33 wherein said composition is in the form of a prerolmed structure such as a film, rod, tube, bead, foam or ring or a viscous liquid, gel, dispersion, suspension, spray or viscous solution.
39. The method according to claim 33 wherein said composition includes a bioactive agent.
40. A method for reducing or preventing adhesions in a patient comprising exposing tissue which has been subjected to tissue damage and is at risk for the formation of adhesions to a prepolymerized polymeric composition comprising polymers of the chemical structure:

where j, k and m are positive integers, R is an ethylene or propylene group with the proviso that R is not exclusively a propylene group when R' and R''' contain an absence of poly(ethylene oxide), R' is a C2 to C12 alkylene group, a cycloalkyl or cycloalkyl-containing group, an aryl or aryl-containing group, 4,4'-diphenylmethane, toluene, naphthalene, 4,4'-dicyclohexylmethane, cyclohexyl, 3,3'-dimethylphenyl, 3,3'-dimethyl-diphenylmethane, 4,6'-xylylene, 3,5,5-trimethylcyclohexyl, 2,2,4-trimethylhexamethylene, p-phenylene, or a poly(ethylene oxide) containing or poly(ethylene oxide) rich chain, R''' is selected from the group consisting of poly(ethylene oxide), poly(ethylene oxide)-co-poly(propylene oxide), a poly(ethylene oxide)-rich chain, a diol, a diamine, a dicarboxylic acid and an ABA triblock wherein A is a polyester unit and B is selected from the group consisting of poly(ethylene oxide), poly(ethylene oxide)-co-poly(propylene oxide), a poly(ethylene oxide)-rich chain, a diol, a diamine, and a dicarboxylic acid and R1 is H or CH3, said polymeric composition having an EO/LA ratio which falls within the range of about 0.1 to about 100.
41. The method according to claim 40 wherein said diol is selected from the group consisting of ethylene glycol, butanediol, OH-terminated polycaprolactone, poly(propylene glycol), OH-terminated polyester or oligoesters, tartaric acid, said diamine is selected from the group consisting of ethylene diamine, hexamethylene diamine, amino acids, and oligopeptides and said dicarboxylic acid is selected from the group consisting of succinic acid, sebacic acid, adipic acid, malic acid, oxalic acid, maleic acid, fumaric acid, COOH-terminated polycaprolactone, and COOH-terminated polyesters or oligoesters.
42. The method according to claim 40 wherein R1 is CH3.
43. The method according to claim 40 wherein m is 4 to about 5,000, R1 is CH3 and R is an ethylene group.
44. The method according to claim 40 wherein m is about 30 to about 230, R1 is CH3 and R is an ethylene group.
45. The method according to claim 40 wherein R' is a C6 alkylene group.
46. The method according to claim 40 wherein said composition is in the form of a preformed structure such as a film, rod, tube, bead, foam or ring or a viscous liquid, dispersion, suspension, viscous solution, spray or gel.
47. The method according to claim 40 wherein a and b are the same integer
48. The method according to claim 40 wherein said polymeric composition includes a bioactive agent.
49. The method according to claim 40 where R''' is poly(ethylene oxide) and has a molecular weight ranging from about 200 Da to about 10,000 Da.
50. The method according to claim 40 wherein R' is a C2 to C8 alkylene group.
51. A method for reducing or preventing adhesions in a patient comprising exposing tissue which has been subjected to tissue damage and is at risk for the formation of adhesions to a prepolymerized polymeric composition comprising chain extended, coupled or crosslinked ABA
triblocks or AB diblocks, where A is an aliphatic polyester and B is a compound selected from the group consisting of a diol, a diamine and a dicarboxylic acid, wherein said ABA triblock or AB
diblock is chain extended, coupled or crosslinked with an amount of at least one compound comprising poly(ethylene oxide) effective to provide an EO/LA ratio of said polymeric composition which falls within the range of about 0.1 to about 100.
52. The method according to claim 51 wherein said diol is selected from the group consisting of ethylene glycol, butanediol, OH-terminated polycaprolactone, poly(propylene glycol), OH-terminated polyester or oligoesters, tartaric acid, said diamine is selected from the group consisting of ethylene diamine, hexamethylene diamine, amino acids, and oligopeptides and said dicarboxylic acid is selected from the group consisting of succinic acid, sebacic acid, adipic acid, malic acid, oxalic acid, maleic acid, fumaric acid, COOH-terminated polycaprolactone, and COOH-terminated polyesters or oligoesters.
53. The method according to claim 51 wherein said polyester is derived from the polymerization of monomers selected from the group consisting of lactic acid, lactide, glycolic acid, glycolide, .beta.-propiolactone, .epsilon.-caprolactone, .delta.-glutarolactone, .delta.-valerolactone, .beta.-butyrolactone, pivalolactone, .alpha.,.alpha.-diethylpropiolactone, ethylene carbonate, trimethylene carbonate, .gamma.-butyrolactone, p-dioxanone, 1,4-dioxepan-2-one, 3-methyl-1,4-dioxane-2,5-dione, 3,3,-dimethyl-1-4-dioxane-2,5-dione, cyclic esters of .alpha.-hydroxybutyric acid, .alpha.-hydroxyvaleric acid, .alpha.-hydroxyisovaleric acid, .alpha.-hydroxycaproic acid, .alpha.-hydroxy-.alpha.-ethylbutyric acid, .alpha.-hydroxyisocaproic acid, .alpha.-hydroxy-.alpha.-methyl valeric acid, .alpha.-hydroxyheptanoic acid, .alpha.-hydroxystearic acid, .alpha.-hydroxylignoceric acid, salicylic acid and mixtures, thereof.
54. The method according to claim 51 wherein said polyester comprises poly(aliphatic hydroxy carboxylic acid).
55. The method according to claim 51 wherein said polyester comprises poly(aliphatic .alpha.-hydroxy carboxylic acid).
56. The method according to claim 51 wherein said polyester is obtained from polymerization of an aliphatic hydroxycarboxylic acid or ester selected from the group consisting of L-lactic acid, D,L-lactic acid, glycolic acid, L-lactide, D,L-lactide, glycolide or mixtures thereof.
57. The method according to claim 51 wherein said A block is between about 1 and 400 carboxylic acid units in size and said B block is varies in size from about 100 Da to about 200,000 Da.
58. The method according to claim 51 wherein said A block comprises carboxylic acid units derived from L-lactide or D,L-lactide and said B block is comprised of a diol.
59. The method according to claim 51 wherein said A block is approximately 6 to 30 carboxylic acid units in length and said B block is comprised of ethylene glycol or butane diol.
60. The method according to claim 51 wherein said composition is in the form of a preformed structure such as a film, rod, tube, bead, foam or ring or a dispersion, suspension, gel, liquid, spray or viscous solution.
61. The method according to claim 51 wherein said composition further includes a bioactive agent.
62. The method according to claim 51 wherein said composition is chain extended or coupled with a diisocyanate of the general formula:

where R' comprises a poly(oxyalkylene)-containing or poly(oxyethylene) rich chain.
63. The method according to claim 51 wherein said composition is chain extended or coupled with a compound of the general formula:

where R'' is a polyoxyalkylene chain comprised of poly(ethylene oxide), poly(ethylene oxide)-co-poly(propylene oxide) or is a poly(ethylene oxide) rich chain and L is hydroxyl, a halide selected from Cl, I or Br or an ester group.
64. The method according to claim 63 wherein R'' is poly(ethylene oxide).
65. The method according to claim 51 wherein said composition is crosslinked.
66. The method according to claim 51 wherein said composition is crosslinked.
67. A composition for use in reducing or preventing adhesions in a patient comprising a polymer of the chemical structure:

where m and a are positive integers, R is an ethylene group or propylene group with the proviso that R is not exclusively a propylene group, M is a non-reactive group and R1 is H or CH3 said composition having an EO/LA ratio ranging from about 0.1 to about 100.
68. The composition according to claim 67 wherein R1 is CH3.
69. The composition according to claim 67 wherein said non-reactive group is a C1 to C12 alkyl group, an aryl group, an aralkyl group or a substituted C1 to C12 alkyl group, aryl group, aralkyl group or a blocking group.
70. The composition according to claim 67 wherein m is 4 to about 5,000, R1 is CH3 and R is an ethylene group.
71. The composition according to claim 67 wherein m is about 30 to about 230, R1 is CH3 and R is an ethylene group.
72. The composition according to claim 67 wherein said polymeric composition includes a bioactive agent.
73. A composition for use in reducing or preventing adhesions in a patient comprising a polymer of the chemical structure:

where m and x are positive integers, R is an ethylene group or propylene group with the proviso that R is not exclusively a propylene group when R'' contains an absence of poly(ethylene oxide), M is a non-reactive group, R'' is a C0 to C12 alkylene group or a hydroxyl or carboxylic acid substituted alkyl group, a cycloalkyl, a hydroxyl-containing cycloalkyl, or cycloalkyl-containing group, an aryl or aryl-containing group, or a polyoxyalkylene chain-containing group comprised of poly(ethylene oxide), poly(ethylene oxide)-co-poly(propylene oxide) or a poly(ethylene oxide) rich chain, R1 is H or CH3 and M is a non-reactive group, said polymeric composition having an EO/LA ratio which falls within the range of about 0.1 to about 100.
74. The composition according to claim 73 wherein said non-reactive group is a C1 to C12 alkyl group, an aryl group, an aralkyl group or a substituted C1 to C12 alkyl group, an aryl group, an aralkyl group or a blocking group.
75. The composition according to claim 73 where M is methyl or ethyl.
76. A composition for use in reducing or preventing adhesions in a patient comprising a polymer of the chemical structure:

where m and a are positive integers, R is an ethylene group and/or propylene group with the proviso that R is not exclusively a propylene group when R' contains an absence of poly(ethylene oxide), M is a non-reactive group, R' is a C2 to C12 alkylene group, a cycloalkyl or cycloalkyl-containing group, an aryl or aryl-containing group, 4,4'-diphenylmethane, toluene, naphthalene, 4,4'-dicyclohexylmethane, cyclohexyl, 3,3'-dimethylphenyl, 3,3'-dimethyl-diphenylmethane, 4,6'-xylylene, 3,5,5-trimethylcyclohexyl, 2,2,4-trimethylhexamethylene, p-phenylene or a poly(ethylene oxide) containing or poly(ethylene oxide) rich chain and R1 is H or CH3, said polymeric composition having an EO/LA ratio which falls within the range of about 0.1 to about 100.
77. The composition according to claim 66 wherein said non-reactive group is a C1 to C12 alkyl group, an aryl group, an aralkyl group or a substituted C1 to C12 alkyl group, an aryl group, an aralkyl group or a blocking group.
78. The composition according to claim 67 where M is methyl or ethyl.
79. A composition for use in reducing or preventing adhesions in a patient comprising a polymer of the chemical structure:

where m and k are positive integers, R is an ethylene or propylene group with the proviso that R is not exclusively a propylene group when R' and R''' contain an absence of poly(ethylene oxide), R' is a C2 to C12 alkylene group, a cycloalkyl or cycloalkyl-containing group, an aryl or aryl-containing group, 4,4'-diphenylmethane, toluene, naphthalene, 4,4'-dicyclohexylmethane, cyclohexyl, 3,3'-dimethylphenyl, 3,3'-dimethyl-diphenylmethane, 4,6'-xylylene, 3,5,5-trimethylcyclohexyl, 2,2,4-trimethylhexamethylene, p-phenylene or a poly(ethylene oxide) containing or poly(ethylene oxide) rich chain, R''' is selected from the group consisting of poly(ethylene oxide), poly(ethylene oxide)-co-poly(propylene oxide), a poly(ethylene oxide)-rich chain, a diol, a diamine, a dicarboxylic acid or an ABA triblock, wherein A is a polyester unit and B is selected from the group consisting of poly(ethylene oxide), poly(ethylene oxide)-co-poly(propylene oxide), a poly(ethylene oxide)-rich chain, a diol, a diamine, and a dicarboxylic acid, R1 is H or CH3 and M is a non-reactive group, said polymeric composition having an EO/LA ratio which falls within the range of about 0.1 to about 100.
80. The method according to claim 79 wherein said diol is selected from the group consisting of ethylene glycol, butanediol, OH-terminated polycaprolactone, poly(propylene glycol), OH-terminated polyester or oligoesters, tartaric acid, said diamine is selected from the group consisting of ethylene diamine, hexamethylene diamine, amino acids, and oligopeptides and said dicarboxylic acid is selected from the group consisting of succinic acid, sebacic acid, adipic acid, malic acid, oxalic acid, maleic acid, fumaric acid, COOH-terminated polycaprolactone, and COOH-terminated polyesters or oligoesters.
81. The composition according to claim 79 wherein said non-reactive group is a C1 to C12 alkyl group, an aryl group, an aralkyl group or a substituted C1 to C12 alkyl group, an aryl group, an aralkyl group or a blocking group.
82. The composition according to claim 79 where M is methyl or ethyl.
83. A composition for use in reducing or preventing adhesions in a patient comprising a polymer of the chemical structure: .

where m and k are positive integers, R is an ethylene or propylene group with the proviso that R is not exclusively ethylene where R' contains an absence of poly(ethylene oxide), R' is a C2 to C12 alkylene group, a cycloalkyl or cycloalkyl-containing group, an aryl or aryl-containing group, 4,4'-diphenylmethane, toluene, naphthalene, 4,4'-dicyclohexylmethane, cyclohexyl, 3,3'-dimethylphenyl, 3,3'-dimethyl-diphenylmethane, 4,6'-xylylene, 3,5,5-trimethylcyclohexyl, 2,2,4-trimethylhexamethylene, p-phenylene or a poly(ethylene oxide) containing or poly(ethylene oxide) rich chain and K is any group derived from a compound which is unable to initiate ring opening polymerization of a starting lactone, said polymeric composition having an EO/LA ratio which falls within the range of about 0.1 to about 100.
84. The composition according to claim 83 wherein K is a C1 to C12 alkyl group, an aryl group, an aralkyl group or a substituted C1 to C12 alkyl group, an aryl group, an aralkyl group, a C=C- containing group.
85. The composition according to claim 83 where K is methyl or ethyl.
86. A composition for use in reducing or preventing adhesions in a patient comprising a polymer of the chemical structure:

where m and x are positive integers, is an ethylene or propylene group with the proviso that R is not exclusively a propylene group when R'' and R''' contain an absence of poly(ethylene oxide), R1 is a hydrogen or methyl group, R'' is a C0 to C12 alkylene group or a hydroxyl or carboxylic acid substituted alkyl group, a cycloalkyl, a hydroxyl-containing cycloalkyl, or cycloalkyl-containing group, an aryl or aryl-containing group, or a polyoxyalkylene chain-containing group comprised of poly(ethylene oxide), poly(ethylene oxide)-co-poly(propylene oxide) or a poly(ethylene oxide) rich chain, R''' is selected from the group consisting of poly(ethylene oxide), poly(ethylene oxide)-co-poly(propylene oxide), a poly(ethylene oxide)-rich chain, a diol, a diamine, a dicarboxylic acid and an ABA triblock, wherein A is a polyester unit and B is selected from the group consisting of poly(ethylene oxide), poly(ethylene oxide)-co-poly(propylene oxide), a poly(ethylene oxide)-rich chain, a diol, a diamine, and a dicarboxylic acid, R1 is H or CH3 and M is a non-reactive group, said polymeric composition having an EO/LA ratio which falls within the range of about 0.1 to about 100.
87. The method according to claim 86 wherein said diol is selected from the group consisting of ethylene glycol, butanediol, OH-terminated polycaprolactone, poly(propylene glycol), OH-terminated polyester or oligoesters, tartaric acid, said diamine is selected from the group consisting of ethylene diamine, hexamethylene diamine, amino acids, and oligopeptides and said dicarboxylic acid is selected from the group consisting of succinic acid, sebacic acid, adipic acid, malic acid, oxalic acid, maleic acid, fumaric acid, COOH-terminated polycaprolactone, and COOH-terminated polyesters or oligoesters.
88. The composition according to claim 86 wherein said non-reactive group is a C1 to C12 alkyl group, an aryl group, an aralkyl group or a substituted C1 to C12 alkyl group, an aryl group, an aralkyl group or a blocking group.
89. The composition according to claim 86 where M is methyl or ethyl.
90. A composition for use in reducing or preventing adhesions in a patient comprising a polymer of the chemical structure:

where m and a are positive integers, R is an ethylene group and/or propylene group with the proviso that R is not exclusively a propylene group when R' contains an absence of poly(ethylene oxide), M is a non-reactive group, R' is a C2 to C12 alkylene group, a cycloalkyl or cycloalkyl-containing group, an aryl or aryl-containing group, 4,4'-diphenylmethane, toluene, naphthalene, 4,4'-dicyclohexylmethane, cyclohexyl, 3,3'-dimethylphenyl, 3,3'-dimethyl-diphenylmethane, 4,6'-xylylene, 3,5,5-trimethylcyclohexyl, 2,2,4-trimethylhexamethylene, p-phenylene or a poly(ethylene oxide) containing or poly(ethylene oxide) rich chain, M is a non-reactive group, R1 is H or CH3, said polymeric composition having an EO/LA ratio which falls within the range of about 0.1 to about 100.
91. The composition according to claim 90 wherein said non-reactive group is a C1 to C12 alkyl group, an aryl group, an aralkyl group or a substituted C1 to C12 alkyl group, an aryl group, an aralkyl group or a blocking group.
92. The composition according to claim 91 where M is methyl or ethyl.
CA2259603A 1996-07-11 1997-07-11 Use of polymeric compositions for reducing or eliminating post-surgical adhesion formation Expired - Fee Related CA2259603C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US08/678,762 US5711958A (en) 1996-07-11 1996-07-11 Methods for reducing or eliminating post-surgical adhesion formation
US08/678,762 1996-07-11
PCT/US1997/012168 WO1998002171A1 (en) 1996-07-11 1997-07-11 Methods and compositions for reducing or eliminating post-surgical adhesion formation

Publications (2)

Publication Number Publication Date
CA2259603A1 true CA2259603A1 (en) 1998-01-22
CA2259603C CA2259603C (en) 2011-02-08

Family

ID=24724165

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2259603A Expired - Fee Related CA2259603C (en) 1996-07-11 1997-07-11 Use of polymeric compositions for reducing or eliminating post-surgical adhesion formation

Country Status (11)

Country Link
US (2) US5711958A (en)
EP (1) EP0939639B1 (en)
JP (1) JP2000514457A (en)
KR (1) KR20000023724A (en)
AT (1) ATE330618T1 (en)
AU (1) AU735698B2 (en)
BR (1) BR9710243A (en)
CA (1) CA2259603C (en)
DE (1) DE69736186T2 (en)
ES (1) ES2262182T3 (en)
WO (1) WO1998002171A1 (en)

Families Citing this family (232)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5817327A (en) * 1994-07-27 1998-10-06 The Trustees Of The University Of Pennsylvania Incorporation of biologically active molecules into bioactive glasses
US6696499B1 (en) * 1996-07-11 2004-02-24 Life Medical Sciences, Inc. Methods and compositions for reducing or eliminating post-surgical adhesion formation
US7009034B2 (en) * 1996-09-23 2006-03-07 Incept, Llc Biocompatible crosslinked polymers
US20090324721A1 (en) * 1996-09-23 2009-12-31 Jack Kennedy Hydrogels Suitable For Use In Polyp Removal
US8003705B2 (en) 1996-09-23 2011-08-23 Incept Llc Biocompatible hydrogels made with small molecule precursors
US6566406B1 (en) * 1998-12-04 2003-05-20 Incept, Llc Biocompatible crosslinked polymers
US6776792B1 (en) * 1997-04-24 2004-08-17 Advanced Cardiovascular Systems Inc. Coated endovascular stent
US7192984B2 (en) * 1997-06-17 2007-03-20 Fziomed, Inc. Compositions of polyacids and polyethers and methods for their use as dermal fillers
US20040096422A1 (en) * 1997-06-17 2004-05-20 Schwartz Herbert E. Compositions of polyacids and polyethers and methods for their use in reducing pain
US20050074495A1 (en) * 1997-06-17 2005-04-07 Fziomed, Inc. Compositions of polyacids and methods for their use in reducing adhesions
US6869938B1 (en) 1997-06-17 2005-03-22 Fziomed, Inc. Compositions of polyacids and polyethers and methods for their use in reducing adhesions
US6211249B1 (en) 1997-07-11 2001-04-03 Life Medical Sciences, Inc. Polyester polyether block copolymers
US6201072B1 (en) * 1997-10-03 2001-03-13 Macromed, Inc. Biodegradable low molecular weight triblock poly(lactide-co- glycolide) polyethylene glycol copolymers having reverse thermal gelation properties
US6541033B1 (en) * 1998-06-30 2003-04-01 Amgen Inc. Thermosensitive biodegradable hydrogels for sustained delivery of leptin
US7347850B2 (en) * 1998-08-14 2008-03-25 Incept Llc Adhesion barriers applicable by minimally invasive surgery and methods of use thereof
US6514534B1 (en) * 1998-08-14 2003-02-04 Incept Llc Methods for forming regional tissue adherent barriers and drug delivery systems
US20080114092A1 (en) * 1998-12-04 2008-05-15 Incept Llc Adhesion barriers applicable by minimally invasive surgery and methods of use thereof
US6451346B1 (en) * 1998-12-23 2002-09-17 Amgen Inc Biodegradable pH/thermosensitive hydrogels for sustained delivery of biologically active agents
US6338731B1 (en) * 1999-03-17 2002-01-15 Ntero Surgical, Inc. Method and systems for reducing surgical complications
US6645198B1 (en) 1999-03-17 2003-11-11 Ntero Surgical, Inc. Systems and methods for reducing post-surgical complications
US6520185B1 (en) 1999-03-17 2003-02-18 Ntero Surgical, Inc. Systems and methods for reducing post-surgical complications
EP2305324B1 (en) 1999-03-25 2014-09-17 Metabolix, Inc. Medical devices and applications of polyhydroxyalkanoate polymers
US6469132B1 (en) * 1999-05-05 2002-10-22 Mcgill University Diblock copolymer and use thereof in a micellar drug delivery system
US6579951B1 (en) * 1999-06-08 2003-06-17 Life Medical Sciences, Inc. Chain-extended or crosslinked polyethylene oxide/polypropylene oxide/polyethylene oxide block polymer with optional polyester blocks
US6423818B1 (en) * 1999-07-30 2002-07-23 Takehisa Matsuda Coumarin endcapped absorbable polymers
US7807211B2 (en) * 1999-09-03 2010-10-05 Advanced Cardiovascular Systems, Inc. Thermal treatment of an implantable medical device
US6790228B2 (en) * 1999-12-23 2004-09-14 Advanced Cardiovascular Systems, Inc. Coating for implantable devices and a method of forming the same
US20070032853A1 (en) * 2002-03-27 2007-02-08 Hossainy Syed F 40-O-(2-hydroxy)ethyl-rapamycin coated stent
US20050238686A1 (en) * 1999-12-23 2005-10-27 Advanced Cardiovascular Systems, Inc. Coating for implantable devices and a method of forming the same
US6566345B2 (en) 2000-04-28 2003-05-20 Fziomed, Inc. Polyacid/polyalkylene oxide foams and gels and methods for their delivery
US7592017B2 (en) 2000-03-10 2009-09-22 Mast Biosurgery Ag Resorbable thin membranes
KR100795613B1 (en) * 2000-03-10 2008-01-21 마스트 바이오서저리 아게 Resorbable Micro-Membrane for Attenuation of Scar Tissue
US20050031662A1 (en) * 2001-04-24 2005-02-10 Impres Medical, Inc. Bioreactive methods and devices for treating uterine bleeding
EP1278480A2 (en) * 2000-04-25 2003-01-29 Impres Medical, Inc. Method and apparatus for creating intrauterine adhesions
AU2001259177A1 (en) * 2000-04-28 2001-11-12 Fziomed, Inc. Polyacid/polyalkylene oxide foams and gels and methods for their delivery
US6953560B1 (en) 2000-09-28 2005-10-11 Advanced Cardiovascular Systems, Inc. Barriers for polymer-coated implantable medical devices and methods for making the same
US6783793B1 (en) * 2000-10-26 2004-08-31 Advanced Cardiovascular Systems, Inc. Selective coating of medical devices
US7807210B1 (en) * 2000-10-31 2010-10-05 Advanced Cardiovascular Systems, Inc. Hemocompatible polymers on hydrophobic porous polymers
US7763769B2 (en) * 2001-02-16 2010-07-27 Kci Licensing, Inc. Biocompatible wound dressing
US7700819B2 (en) 2001-02-16 2010-04-20 Kci Licensing, Inc. Biocompatible wound dressing
US6775575B2 (en) 2001-02-26 2004-08-10 D. Bommi Bommannan System and method for reducing post-surgical complications
US20020192286A1 (en) * 2001-03-27 2002-12-19 Macromed, Incorporated Biodegradable triblock copolymers as solubilizing agents for drugs and method of use thereof
US20040185101A1 (en) * 2001-03-27 2004-09-23 Macromed, Incorporated. Biodegradable triblock copolymers as solubilizing agents for drugs and method of use thereof
US6780424B2 (en) * 2001-03-30 2004-08-24 Charles David Claude Controlled morphologies in polymer drug for release of drugs from polymer films
US7056967B2 (en) * 2001-04-10 2006-06-06 Ciba Specialty Chemicals Corporation Stabilized medium and high voltage cable insulation composition
US6743462B1 (en) * 2001-05-31 2004-06-01 Advanced Cardiovascular Systems, Inc. Apparatus and method for coating implantable devices
US6695920B1 (en) * 2001-06-27 2004-02-24 Advanced Cardiovascular Systems, Inc. Mandrel for supporting a stent and a method of using the mandrel to coat a stent
US8741378B1 (en) 2001-06-27 2014-06-03 Advanced Cardiovascular Systems, Inc. Methods of coating an implantable device
US6565659B1 (en) * 2001-06-28 2003-05-20 Advanced Cardiovascular Systems, Inc. Stent mounting assembly and a method of using the same to coat a stent
US7682669B1 (en) 2001-07-30 2010-03-23 Advanced Cardiovascular Systems, Inc. Methods for covalently immobilizing anti-thrombogenic material into a coating on a medical device
US20030082235A1 (en) * 2001-08-13 2003-05-01 Yissum Research Development Company Of The Hebrew University Of Jerusalem Novel reverse thermo-sensitive block copolymers
US8303651B1 (en) 2001-09-07 2012-11-06 Advanced Cardiovascular Systems, Inc. Polymeric coating for reducing the rate of release of a therapeutic substance from a stent
US7037527B2 (en) * 2002-01-25 2006-05-02 University Of Rhode Island Bifunctionalized polyester material for surface treatment and biomodification
CA2419831A1 (en) * 2002-02-28 2003-08-28 Macropore Biosurgery, Inc. Methods for governing bone growth
AU2003225516A1 (en) * 2002-03-26 2003-10-08 Yissum Research Development Company Of The Hebrew University Of Jerusalem Responsive biomedical composites
US7649023B2 (en) * 2002-06-11 2010-01-19 Novartis Ag Biodegradable block copolymeric compositions for drug delivery
US7217426B1 (en) 2002-06-21 2007-05-15 Advanced Cardiovascular Systems, Inc. Coatings containing polycationic peptides for cardiovascular therapy
US7056523B1 (en) 2002-06-21 2006-06-06 Advanced Cardiovascular Systems, Inc. Implantable medical devices incorporating chemically conjugated polymers and oligomers of L-arginine
US6994867B1 (en) 2002-06-21 2006-02-07 Advanced Cardiovascular Systems, Inc. Biocompatible carrier containing L-arginine
US8506617B1 (en) 2002-06-21 2013-08-13 Advanced Cardiovascular Systems, Inc. Micronized peptide coated stent
US7011842B1 (en) 2002-06-21 2006-03-14 Advanced Cardiovascular Systems, Inc. Polycationic peptide coatings and methods of making the same
US7794743B2 (en) * 2002-06-21 2010-09-14 Advanced Cardiovascular Systems, Inc. Polycationic peptide coatings and methods of making the same
US7070798B1 (en) 2002-06-21 2006-07-04 Advanced Cardiovascular Systems, Inc. Coatings for implantable medical devices incorporating chemically-bound polymers and oligomers of L-arginine
US7033602B1 (en) * 2002-06-21 2006-04-25 Advanced Cardiovascular Systems, Inc. Polycationic peptide coatings and methods of coating implantable medical devices
WO2004010854A2 (en) * 2002-07-31 2004-02-05 Mast Biosurgery Ag Apparatus and method for preventing adhesions between an implant and surrounding tissues
US8048444B2 (en) 2002-07-31 2011-11-01 Mast Biosurgery Ag Apparatus and method for preventing adhesions between an implant and surrounding tissues
EP1542613B1 (en) * 2002-07-31 2019-04-10 Mast Biosurgery AG Resorbable thin membranes
CA2495818A1 (en) * 2002-08-20 2004-03-04 John N. Semertzides Compositions comprising epithelial cells for the treatment and prevention of tissue adhesions
US7704520B1 (en) * 2002-09-10 2010-04-27 Mast Biosurgery Ag Methods of promoting enhanced healing of tissues after cardiac surgery
US20040226620A1 (en) 2002-09-26 2004-11-18 Daniel Therriault Microcapillary networks
US6896965B1 (en) * 2002-11-12 2005-05-24 Advanced Cardiovascular Systems, Inc. Rate limiting barriers for implantable devices
US7053125B2 (en) * 2002-11-14 2006-05-30 The Board Of Trustees Of The University Of Illinois Controlled dispersion of colloidal suspension by comb polymers
US7776926B1 (en) * 2002-12-11 2010-08-17 Advanced Cardiovascular Systems, Inc. Biocompatible coating for implantable medical devices
US7758880B2 (en) * 2002-12-11 2010-07-20 Advanced Cardiovascular Systems, Inc. Biocompatible polyacrylate compositions for medical applications
US7074276B1 (en) * 2002-12-12 2006-07-11 Advanced Cardiovascular Systems, Inc. Clamp mandrel fixture and a method of using the same to minimize coating defects
US20060002968A1 (en) * 2004-06-30 2006-01-05 Gordon Stewart Anti-proliferative and anti-inflammatory agent combination for treatment of vascular disorders
US7094256B1 (en) 2002-12-16 2006-08-22 Advanced Cardiovascular Systems, Inc. Coatings for implantable medical device containing polycationic peptides
US8435550B2 (en) * 2002-12-16 2013-05-07 Abbot Cardiovascular Systems Inc. Anti-proliferative and anti-inflammatory agent combination for treatment of vascular disorders with an implantable medical device
US7758881B2 (en) * 2004-06-30 2010-07-20 Advanced Cardiovascular Systems, Inc. Anti-proliferative and anti-inflammatory agent combination for treatment of vascular disorders with an implantable medical device
US7063884B2 (en) * 2003-02-26 2006-06-20 Advanced Cardiovascular Systems, Inc. Stent coating
US20060083767A1 (en) * 2003-02-27 2006-04-20 Kai Deusch Surgical prosthesis having biodegradable and nonbiodegradable regions
KR20050118725A (en) 2003-04-10 2005-12-19 데이진 가부시키가이샤 Biodegradable film having honeycomb structure
US7279174B2 (en) * 2003-05-08 2007-10-09 Advanced Cardiovascular Systems, Inc. Stent coatings comprising hydrophilic additives
IL155866A0 (en) * 2003-05-12 2003-12-23 Yissum Res Dev Co Responsive polymeric system
WO2006028431A1 (en) * 2003-05-21 2006-03-16 Impres Medical, Inc. Intrauterine implant and methods of use
US7141617B2 (en) 2003-06-17 2006-11-28 The Board Of Trustees Of The University Of Illinois Directed assembly of three-dimensional structures with micron-scale features
US20050118344A1 (en) 2003-12-01 2005-06-02 Pacetti Stephen D. Temperature controlled crimping
FI20045223A (en) * 2004-06-15 2005-12-16 Bioretec Oy A multifunctional biodegradable composite and a surgical implant comprising said composite
US20050021127A1 (en) * 2003-07-21 2005-01-27 Kawula Paul John Porous glass fused onto stent for drug retention
US7785512B1 (en) 2003-07-31 2010-08-31 Advanced Cardiovascular Systems, Inc. Method and system of controlled temperature mixing and molding of polymers with active agents for implantable medical devices
US20100266663A1 (en) * 2003-09-10 2010-10-21 Calhoun Christopher J Tissue-treating implantable compositions
US20100114328A1 (en) * 2003-09-10 2010-05-06 Milbocker Michael T Resorbable membrane implanting methods for reducing adhesions
US7198675B2 (en) * 2003-09-30 2007-04-03 Advanced Cardiovascular Systems Stent mandrel fixture and method for selectively coating surfaces of a stent
US9066912B2 (en) * 2003-11-17 2015-06-30 Ethicon, Inc. Drug-enhanced adhesion prevention
US9114198B2 (en) * 2003-11-19 2015-08-25 Advanced Cardiovascular Systems, Inc. Biologically beneficial coatings for implantable devices containing fluorinated polymers and methods for fabricating the same
US20050208095A1 (en) * 2003-11-20 2005-09-22 Angiotech International Ag Polymer compositions and methods for their use
US8192752B2 (en) * 2003-11-21 2012-06-05 Advanced Cardiovascular Systems, Inc. Coatings for implantable devices including biologically erodable polyesters and methods for fabricating the same
WO2005059003A1 (en) * 2003-12-15 2005-06-30 The Children's Hospital Of Philadelphia Novel polyesters
US7220816B2 (en) * 2003-12-16 2007-05-22 Advanced Cardiovascular Systems, Inc. Biologically absorbable coatings for implantable devices based on poly(ester amides) and methods for fabricating the same
US7435788B2 (en) * 2003-12-19 2008-10-14 Advanced Cardiovascular Systems, Inc. Biobeneficial polyamide/polyethylene glycol polymers for use with drug eluting stents
EP1555278A1 (en) 2004-01-15 2005-07-20 Innocore Technologies B.V. Biodegradable multi-block co-polymers
US8277831B2 (en) * 2004-02-17 2012-10-02 Advanced Technologies And Regenerative Medicine, Llc. Drug-enhanced adhesion prevention
US8685431B2 (en) * 2004-03-16 2014-04-01 Advanced Cardiovascular Systems, Inc. Biologically absorbable coatings for implantable devices based on copolymers having ester bonds and methods for fabricating the same
US8778014B1 (en) 2004-03-31 2014-07-15 Advanced Cardiovascular Systems, Inc. Coatings for preventing balloon damage to polymer coated stents
US20050265960A1 (en) * 2004-05-26 2005-12-01 Pacetti Stephen D Polymers containing poly(ester amides) and agents for use with medical articles and methods of fabricating the same
US8293890B2 (en) * 2004-04-30 2012-10-23 Advanced Cardiovascular Systems, Inc. Hyaluronic acid based copolymers
US7820732B2 (en) * 2004-04-30 2010-10-26 Advanced Cardiovascular Systems, Inc. Methods for modulating thermal and mechanical properties of coatings on implantable devices
US20050288481A1 (en) * 2004-04-30 2005-12-29 Desnoyer Jessica R Design of poly(ester amides) for the control of agent-release from polymeric compositions
US20050255091A1 (en) * 2004-05-14 2005-11-17 Loomis Gary L Hydrogels for biomedical applications
US7758654B2 (en) * 2004-05-20 2010-07-20 Kensey Nash Corporation Anti-adhesion device
US9561309B2 (en) * 2004-05-27 2017-02-07 Advanced Cardiovascular Systems, Inc. Antifouling heparin coatings
US7563780B1 (en) 2004-06-18 2009-07-21 Advanced Cardiovascular Systems, Inc. Heparin prodrugs and drug delivery stents formed therefrom
US20050287184A1 (en) 2004-06-29 2005-12-29 Hossainy Syed F A Drug-delivery stent formulations for restenosis and vulnerable plaque
US7494665B1 (en) 2004-07-30 2009-02-24 Advanced Cardiovascular Systems, Inc. Polymers containing siloxane monomers
US8357391B2 (en) 2004-07-30 2013-01-22 Advanced Cardiovascular Systems, Inc. Coatings for implantable devices comprising poly (hydroxy-alkanoates) and diacid linkages
US7311980B1 (en) 2004-08-02 2007-12-25 Advanced Cardiovascular Systems, Inc. Polyactive/polylactic acid coatings for an implantable device
US20080091277A1 (en) * 2004-08-13 2008-04-17 Kai Deusch Surgical prosthesis having biodegradable and nonbiodegradable regions
KR100895135B1 (en) * 2004-08-13 2009-05-04 마스트 바이오서저리 아게 Surgical prosthesis having biodegradable and nonbiodegradable regions
US7648727B2 (en) * 2004-08-26 2010-01-19 Advanced Cardiovascular Systems, Inc. Methods for manufacturing a coated stent-balloon assembly
US7244443B2 (en) * 2004-08-31 2007-07-17 Advanced Cardiovascular Systems, Inc. Polymers of fluorinated monomers and hydrophilic monomers
US8110211B2 (en) * 2004-09-22 2012-02-07 Advanced Cardiovascular Systems, Inc. Medicated coatings for implantable medical devices including polyacrylates
US7166680B2 (en) * 2004-10-06 2007-01-23 Advanced Cardiovascular Systems, Inc. Blends of poly(ester amide) polymers
US8603634B2 (en) 2004-10-27 2013-12-10 Abbott Cardiovascular Systems Inc. End-capped poly(ester amide) copolymers
US20060089485A1 (en) * 2004-10-27 2006-04-27 Desnoyer Jessica R End-capped poly(ester amide) copolymers
US7390497B2 (en) * 2004-10-29 2008-06-24 Advanced Cardiovascular Systems, Inc. Poly(ester amide) filler blends for modulation of coating properties
US7481835B1 (en) 2004-10-29 2009-01-27 Advanced Cardiovascular Systems, Inc. Encapsulated covered stent
US20060095122A1 (en) * 2004-10-29 2006-05-04 Advanced Cardiovascular Systems, Inc. Implantable devices comprising biologically absorbable star polymers and methods for fabricating the same
US7214759B2 (en) * 2004-11-24 2007-05-08 Advanced Cardiovascular Systems, Inc. Biologically absorbable coatings for implantable devices based on polyesters and methods for fabricating the same
US8609123B2 (en) * 2004-11-29 2013-12-17 Advanced Cardiovascular Systems, Inc. Derivatized poly(ester amide) as a biobeneficial coating
US7892592B1 (en) 2004-11-30 2011-02-22 Advanced Cardiovascular Systems, Inc. Coating abluminal surfaces of stents and other implantable medical devices
US20060115449A1 (en) * 2004-11-30 2006-06-01 Advanced Cardiovascular Systems, Inc. Bioabsorbable, biobeneficial, tyrosine-based polymers for use in drug eluting stent coatings
US7604818B2 (en) * 2004-12-22 2009-10-20 Advanced Cardiovascular Systems, Inc. Polymers of fluorinated monomers and hydrocarbon monomers
US7419504B2 (en) * 2004-12-27 2008-09-02 Advanced Cardiovascular Systems, Inc. Poly(ester amide) block copolymers
US8007775B2 (en) * 2004-12-30 2011-08-30 Advanced Cardiovascular Systems, Inc. Polymers containing poly(hydroxyalkanoates) and agents for use with medical articles and methods of fabricating the same
US7202325B2 (en) * 2005-01-14 2007-04-10 Advanced Cardiovascular Systems, Inc. Poly(hydroxyalkanoate-co-ester amides) and agents for use with medical articles
US8394410B2 (en) * 2005-01-20 2013-03-12 Massachusetts Institute Of Technology Soft polylactides
US20060216431A1 (en) * 2005-03-28 2006-09-28 Kerrigan Cameron K Electrostatic abluminal coating of a stent crimped on a balloon catheter
US7795467B1 (en) 2005-04-26 2010-09-14 Advanced Cardiovascular Systems, Inc. Bioabsorbable, biobeneficial polyurethanes for use in medical devices
US9119901B2 (en) * 2005-04-28 2015-09-01 Warsaw Orthopedic, Inc. Surface treatments for promoting selective tissue attachment to medical impants
US8414907B2 (en) 2005-04-28 2013-04-09 Warsaw Orthopedic, Inc. Coatings on medical implants to guide soft tissue healing
US8778375B2 (en) 2005-04-29 2014-07-15 Advanced Cardiovascular Systems, Inc. Amorphous poly(D,L-lactide) coating
US7637941B1 (en) 2005-05-11 2009-12-29 Advanced Cardiovascular Systems, Inc. Endothelial cell binding coatings for rapid encapsulation of bioerodable stents
US7622070B2 (en) * 2005-06-20 2009-11-24 Advanced Cardiovascular Systems, Inc. Method of manufacturing an implantable polymeric medical device
US7823533B2 (en) * 2005-06-30 2010-11-02 Advanced Cardiovascular Systems, Inc. Stent fixture and method for reducing coating defects
US8021676B2 (en) 2005-07-08 2011-09-20 Advanced Cardiovascular Systems, Inc. Functionalized chemically inert polymers for coatings
US7785647B2 (en) * 2005-07-25 2010-08-31 Advanced Cardiovascular Systems, Inc. Methods of providing antioxidants to a drug containing product
US7735449B1 (en) 2005-07-28 2010-06-15 Advanced Cardiovascular Systems, Inc. Stent fixture having rounded support structures and method for use thereof
US20080119878A1 (en) * 2005-08-12 2008-05-22 Kai Deusch Surgical prosthesis having biodegradable and nonbiodegradable regions
CA2623561C (en) * 2005-09-27 2015-04-28 Efrat Biopolymers Ltd. Gelling hydrophobic injectable polymer compositions
AU2006321911B2 (en) * 2005-12-06 2012-05-17 Covidien Lp Biocompatible surgical compositions
JP2009518129A (en) * 2005-12-06 2009-05-07 タイコ ヘルスケア グループ リミテッド パートナーシップ Bioabsorbable surgical composition
US20070128246A1 (en) * 2005-12-06 2007-06-07 Hossainy Syed F A Solventless method for forming a coating
US20070135909A1 (en) * 2005-12-08 2007-06-14 Desnoyer Jessica R Adhesion polymers to improve stent retention
US7591841B2 (en) 2005-12-16 2009-09-22 Advanced Cardiovascular Systems, Inc. Implantable devices for accelerated healing
US7976891B1 (en) 2005-12-16 2011-07-12 Advanced Cardiovascular Systems, Inc. Abluminal stent coating apparatus and method of using focused acoustic energy
US7867547B2 (en) 2005-12-19 2011-01-11 Advanced Cardiovascular Systems, Inc. Selectively coating luminal surfaces of stents
US7638156B1 (en) 2005-12-19 2009-12-29 Advanced Cardiovascular Systems, Inc. Apparatus and method for selectively coating a medical article
EP1978975B1 (en) * 2006-02-01 2014-12-24 Samyang Biopharmaceuticals Corporation Composition for inhibiting adhesion
US20070196428A1 (en) * 2006-02-17 2007-08-23 Thierry Glauser Nitric oxide generating medical devices
US7601383B2 (en) * 2006-02-28 2009-10-13 Advanced Cardiovascular Systems, Inc. Coating construct containing poly (vinyl alcohol)
US7713637B2 (en) * 2006-03-03 2010-05-11 Advanced Cardiovascular Systems, Inc. Coating containing PEGylated hyaluronic acid and a PEGylated non-hyaluronic acid polymer
US8013061B2 (en) * 2006-03-08 2011-09-06 The University Of North Carolina At Chapel Hill Polyester based degradable materials and implantable biomedical articles formed therefrom
US20070231363A1 (en) * 2006-03-29 2007-10-04 Yung-Ming Chen Coatings formed from stimulus-sensitive material
US20070259101A1 (en) * 2006-05-02 2007-11-08 Kleiner Lothar W Microporous coating on medical devices
US8304012B2 (en) * 2006-05-04 2012-11-06 Advanced Cardiovascular Systems, Inc. Method for drying a stent
US7985441B1 (en) 2006-05-04 2011-07-26 Yiwen Tang Purification of polymers for coating applications
US8003156B2 (en) * 2006-05-04 2011-08-23 Advanced Cardiovascular Systems, Inc. Rotatable support elements for stents
US7775178B2 (en) * 2006-05-26 2010-08-17 Advanced Cardiovascular Systems, Inc. Stent coating apparatus and method
US9561351B2 (en) * 2006-05-31 2017-02-07 Advanced Cardiovascular Systems, Inc. Drug delivery spiral coil construct
US8568764B2 (en) * 2006-05-31 2013-10-29 Advanced Cardiovascular Systems, Inc. Methods of forming coating layers for medical devices utilizing flash vaporization
US8703167B2 (en) 2006-06-05 2014-04-22 Advanced Cardiovascular Systems, Inc. Coatings for implantable medical devices for controlled release of a hydrophilic drug and a hydrophobic drug
US20080124372A1 (en) * 2006-06-06 2008-05-29 Hossainy Syed F A Morphology profiles for control of agent release rates from polymer matrices
US8778376B2 (en) 2006-06-09 2014-07-15 Advanced Cardiovascular Systems, Inc. Copolymer comprising elastin pentapeptide block and hydrophilic block, and medical device and method of treating
US20070286882A1 (en) * 2006-06-09 2007-12-13 Yiwen Tang Solvent systems for coating medical devices
US8603530B2 (en) 2006-06-14 2013-12-10 Abbott Cardiovascular Systems Inc. Nanoshell therapy
US8114150B2 (en) 2006-06-14 2012-02-14 Advanced Cardiovascular Systems, Inc. RGD peptide attached to bioabsorbable stents
US8048448B2 (en) * 2006-06-15 2011-11-01 Abbott Cardiovascular Systems Inc. Nanoshells for drug delivery
US8017237B2 (en) 2006-06-23 2011-09-13 Abbott Cardiovascular Systems, Inc. Nanoshells on polymers
US9028859B2 (en) * 2006-07-07 2015-05-12 Advanced Cardiovascular Systems, Inc. Phase-separated block copolymer coatings for implantable medical devices
US8703169B1 (en) 2006-08-15 2014-04-22 Abbott Cardiovascular Systems Inc. Implantable device having a coating comprising carrageenan and a biostable polymer
US20080069855A1 (en) * 2006-08-21 2008-03-20 Bonutti Peter M Method of inhibiting the formation of adhesions and scar tissue and reducing blood loss
JP2010506627A (en) * 2006-10-12 2010-03-04 インプレス メディカル, インコーポレイテッド Method and apparatus for occluding a lumen
US8597673B2 (en) * 2006-12-13 2013-12-03 Advanced Cardiovascular Systems, Inc. Coating of fast absorption or dissolution
US7956102B2 (en) * 2007-04-09 2011-06-07 The Board Of Trustees Of The University Of Illinois Sol-gel inks
US8147769B1 (en) 2007-05-16 2012-04-03 Abbott Cardiovascular Systems Inc. Stent and delivery system with reduced chemical degradation
US9056155B1 (en) 2007-05-29 2015-06-16 Abbott Cardiovascular Systems Inc. Coatings having an elastic primer layer
US8109904B1 (en) 2007-06-25 2012-02-07 Abbott Cardiovascular Systems Inc. Drug delivery medical devices
US8048441B2 (en) 2007-06-25 2011-11-01 Abbott Cardiovascular Systems, Inc. Nanobead releasing medical devices
US20090041845A1 (en) * 2007-08-08 2009-02-12 Lothar Walter Kleiner Implantable medical devices having thin absorbable coatings
US20100034869A1 (en) * 2007-08-27 2010-02-11 Joerg Tessmar Block-polymer membranes for attenuation of scar tissue
WO2009081280A2 (en) * 2007-08-27 2009-07-02 Mast Biosurgery Ag Resorbable barrier micro-membranes for attenuation of scar tissue during healing
EP2095832A1 (en) * 2008-02-28 2009-09-02 Bayer MaterialScience AG Post-operative adhesion barriers
TWI388591B (en) * 2008-03-28 2013-03-11 Ind Tech Res Inst Thermosensitive material
US20100003306A1 (en) * 2008-06-08 2010-01-07 Mast Biosurgery Ag Pre-shaped user-formable micro-membrane implants
EP2303351A2 (en) * 2008-06-08 2011-04-06 MAST Biosurgery AG Block-polymer membranes for attenuation of scar tissue
US20090304779A1 (en) * 2008-06-08 2009-12-10 Von Waldburg-Zeil Erich Graf Micro-membrane implant with cusped opening
US7922939B2 (en) 2008-10-03 2011-04-12 The Board Of Trustees Of The University Of Illinois Metal nanoparticle inks
US8187500B2 (en) 2008-10-17 2012-05-29 The Board Of Trustees Of The University Of Illinois Biphasic inks
TWI374903B (en) * 2008-12-31 2012-10-21 Ind Tech Res Inst Biodegradable copolymer hydrogel materials
AU2010229042A1 (en) 2009-03-23 2011-11-10 Kross-Link Laboratories Method for suppressing or preventing fibrous adhesion formation using a multicomponent aqueous oxychlorine composition prepared on-site
US20100310628A1 (en) * 2009-06-08 2010-12-09 Mast Biosurgery Ag Pre-shaped user-formable micro-membrane implants
US20100310632A1 (en) * 2009-06-08 2010-12-09 Von Waldburg-Zeil Erich Graf Micro-membrane implant with cusped opening
US9649331B2 (en) 2009-08-27 2017-05-16 Ara Medical Llc Sprayable polymers as adhesion barriers
US8685433B2 (en) 2010-03-31 2014-04-01 Abbott Cardiovascular Systems Inc. Absorbable coating for implantable device
US9861590B2 (en) * 2010-10-19 2018-01-09 Covidien Lp Self-supporting films for delivery of therapeutic agents
WO2012052527A1 (en) 2010-10-20 2012-04-26 Dsm Ip Assets B.V. Pendant hydrophile bearing biodegradable compositions and related devices
CN103491946B (en) * 2010-12-29 2016-08-10 美蒂森 Biodegradable drug delivery compositions
MY169349A (en) 2011-07-22 2019-03-21 Innocore Tech B V Biodegradable, semi-crystalline, phase separated, thermoplastic multi-block copolymers for controlled release of biologically active compounds
US8998059B2 (en) 2011-08-01 2015-04-07 Ethicon Endo-Surgery, Inc. Adjunct therapy device having driver with cavity for hemostatic agent
US9492170B2 (en) 2011-08-10 2016-11-15 Ethicon Endo-Surgery, Inc. Device for applying adjunct in endoscopic procedure
US9101359B2 (en) 2011-09-13 2015-08-11 Ethicon Endo-Surgery, Inc. Surgical staple cartridge with self-dispensing staple buttress
US8998060B2 (en) 2011-09-13 2015-04-07 Ethicon Endo-Surgery, Inc. Resistive heated surgical staple cartridge with phase change sealant
US9999408B2 (en) 2011-09-14 2018-06-19 Ethicon Endo-Surgery, Inc. Surgical instrument with fluid fillable buttress
US8814025B2 (en) 2011-09-15 2014-08-26 Ethicon Endo-Surgery, Inc. Fibrin pad matrix with suspended heat activated beads of adhesive
US9254180B2 (en) 2011-09-15 2016-02-09 Ethicon Endo-Surgery, Inc. Surgical instrument with staple reinforcement clip
US9125649B2 (en) 2011-09-15 2015-09-08 Ethicon Endo-Surgery, Inc. Surgical instrument with filled staple
US9393018B2 (en) 2011-09-22 2016-07-19 Ethicon Endo-Surgery, Inc. Surgical staple assembly with hemostatic feature
US9198644B2 (en) 2011-09-22 2015-12-01 Ethicon Endo-Surgery, Inc. Anvil cartridge for surgical fastening device
US8985429B2 (en) 2011-09-23 2015-03-24 Ethicon Endo-Surgery, Inc. Surgical stapling device with adjunct material application feature
TWI641396B (en) 2011-09-23 2018-11-21 Bvw控股公司 Medical copolymer
US8899464B2 (en) 2011-10-03 2014-12-02 Ethicon Endo-Surgery, Inc. Attachment of surgical staple buttress to cartridge
US9089326B2 (en) 2011-10-07 2015-07-28 Ethicon Endo-Surgery, Inc. Dual staple cartridge for surgical stapler
EP2612846A1 (en) 2012-01-09 2013-07-10 Bayer MaterialScience AG Beta amino acid esters and use of same
WO2013112381A2 (en) * 2012-01-24 2013-08-01 Bvw Holding Ag New class of anti-adhesion hydrogels with healing aspects
EP2842583A1 (en) 2013-08-29 2015-03-04 Ella-CS, s.r.o. Biodegradable and bioerodible polyurethanes, method of preparation thereof and use thereof
FR3024455B1 (en) * 2014-08-04 2018-03-02 Ecole Nationale Superieure De Chimie De Montpellier COMPOSITION OF COPOLYMERS DIBLOCS AND TRIBLOCS AND ITS USE IN THE PREVENTION OF TISSUE ADHESIONS
WO2016097848A1 (en) 2014-12-18 2016-06-23 Dexcel Pharma Technologies Ltd. Alternating and semi-alternating poly(ester-anhydride) copolymers
US10213530B2 (en) * 2015-06-19 2019-02-26 Toray Industries, Inc. Polymer film and antiadhesive material using the same
HRP20231453T1 (en) 2015-11-16 2024-03-01 Medincell S.A. A method for morselizing and/or targeting pharmaceutically active principles to synovial tissue
AU2017406466A1 (en) 2017-03-29 2019-10-17 Dexcel Pharma Technologies Ltd. Compositions comprising biodegradable copolymers
NL2019957B1 (en) * 2017-11-22 2019-05-29 Suprapolix Bv Supramolecular biomedical polymers
MX2022003975A (en) 2019-10-01 2022-07-19 Innocore Tech Holding B V Biodegradable, phase separated, thermoplastic multi-block copolymer.

Family Cites Families (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3890253A (en) * 1970-12-26 1975-06-17 Idemitsu Kosan Co Reversibly crosslinked polymers
US3912692A (en) * 1973-05-03 1975-10-14 American Cyanamid Co Process for polymerizing a substantially pure glycolide composition
US3997512A (en) * 1973-11-21 1976-12-14 American Cyanamid Company High molecular weight polyester resin, the method of making the same
US4095600A (en) * 1976-06-01 1978-06-20 American Cyanamid Company Normally-solid, bioabsorbable, hydrolyzable, polymeric reaction product
US4118470A (en) * 1976-06-01 1978-10-03 American Cyanamid Company Normally-solid, bioabsorbable, hydrolyzable, polymeric reaction product
US4122129A (en) * 1976-06-01 1978-10-24 American Cyanamid Company Normally-solid, bioabsorbable, hydrolyzable, polymeric reaction product
US4048256A (en) * 1976-06-01 1977-09-13 American Cyanamid Company Normally-solid, bioabsorbable, hydrolyzable, polymeric reaction product
US4343931A (en) * 1979-12-17 1982-08-10 Minnesota Mining And Manufacturing Company Synthetic absorbable surgical devices of poly(esteramides)
US4529792A (en) * 1979-12-17 1985-07-16 Minnesota Mining And Manufacturing Company Process for preparing synthetic absorbable poly(esteramides)
US4346709A (en) * 1980-11-10 1982-08-31 Alza Corporation Drug delivery devices comprising erodible polymer and erosion rate modifier
US4429080A (en) * 1982-07-01 1984-01-31 American Cyanamid Company Synthetic copolymer surgical articles and method of manufacturing the same
NL8202893A (en) * 1982-07-16 1984-02-16 Rijksuniversiteit ORGANIC Tolerant, ANTHITHROMBOGENIC MATERIAL, SUITABLE FOR RECOVERY SURGERY.
US4438253A (en) * 1982-11-12 1984-03-20 American Cyanamid Company Poly(glycolic acid)/poly(alkylene glycol) block copolymers and method of manufacturing the same
US4452973A (en) * 1982-11-12 1984-06-05 American Cyanamid Company Poly(glycolic acid)/poly(oxyethylene) triblock copolymers and method of manufacturing the same
IN166447B (en) * 1985-11-27 1990-05-12 Ethicon Inc
US5133755A (en) * 1986-01-28 1992-07-28 Thm Biomedical, Inc. Method and apparatus for diodegradable, osteogenic, bone graft substitute device
LU86452A1 (en) * 1986-06-02 1988-01-20 Oreal USE OF POLYAMINOAMIDES FOR THE PROTECTION OF HAIR AGAINST ATMOSPHERIC AGGRESSIONS, AND PARTICULARLY AGAINST LIGHT AND METHOD FOR PROTECTING HAIR USING SUCH POLYAMINOAMIDES
US4781183A (en) * 1986-08-27 1988-11-01 American Cyanamid Company Surgical prosthesis
US4857602A (en) * 1986-09-05 1989-08-15 American Cyanamid Company Bioabsorbable surgical suture coating
US4705820A (en) * 1986-09-05 1987-11-10 American Cyanamid Company Surgical suture coating
US4882168A (en) * 1986-09-05 1989-11-21 American Cyanamid Company Polyesters containing alkylene oxide blocks as drug delivery systems
US4716203A (en) * 1986-09-05 1987-12-29 American Cyanamid Company Diblock and triblock copolymers
ES2040719T3 (en) * 1986-09-23 1993-11-01 American Cyanamid Company BIO-ABSORBABLE COATING FOR A SURGICAL ARTICLE.
US4788979A (en) * 1986-09-23 1988-12-06 American Cyanamid Company Bioabsorbable coating for a surgical article
IL82834A (en) * 1987-06-09 1990-11-05 Yissum Res Dev Co Biodegradable polymeric materials based on polyether glycols,processes for the preparation thereof and surgical artiicles made therefrom
DE3730792A1 (en) * 1987-09-14 1989-03-23 Henkel Kgaa TEXTILE TREATMENT AGENTS
US5447966A (en) * 1988-07-19 1995-09-05 United States Surgical Corporation Treating bioabsorbable surgical articles by coating with glycerine, polalkyleneoxide block copolymer and gelatin
US4911926A (en) * 1988-11-16 1990-03-27 Mediventures Inc. Method and composition for reducing postsurgical adhesions
US5093351A (en) * 1989-01-05 1992-03-03 Du Pont Merck Pharmaceutical Company Substituted indole, benzofuran and benzothiophene derivatives as 5-lipoxygenase inhibitors
IL90193A (en) * 1989-05-04 1993-02-21 Biomedical Polymers Int Polurethane-based polymeric materials and biomedical articles and pharmaceutical compositions utilizing the same
US4988777A (en) * 1989-08-23 1991-01-29 Bridgestone/Firestone, Inc. Reduction of acidity of polyesters by melt reaction endcapping with eneamines or Schiff bases
US5075115A (en) * 1990-04-02 1991-12-24 Fmc Corporation Process for polymerizing poly(lactic acid)
US5288496A (en) * 1990-05-15 1994-02-22 Stolle Research & Development Corporation Growth promoters for animals
US5080665A (en) * 1990-07-06 1992-01-14 American Cyanamid Company Deformable, absorbable surgical device
US5278255A (en) * 1990-08-17 1994-01-11 The Dow Chemical Company Unsaturated polyaminopolymer, derivatives thereof and processes for making
US5410016A (en) * 1990-10-15 1995-04-25 Board Of Regents, The University Of Texas System Photopolymerizable biodegradable hydrogels as tissue contacting materials and controlled-release carriers
US5380536A (en) * 1990-10-15 1995-01-10 The Board Of Regents, The University Of Texas System Biocompatible microcapsules
DE4111914A1 (en) * 1991-04-12 1992-10-15 Peter Neuenschwander MATERIAL
US5314969A (en) * 1992-05-11 1994-05-24 Showa Highpolymer Co., Ltd. Polyester sheet
FI92592C (en) * 1992-10-16 1994-12-12 Neste Oy Process for the preparation of a lactic acid-based polyurethane
US5202413A (en) * 1993-02-16 1993-04-13 E. I. Du Pont De Nemours And Company Alternating (ABA)N polylactide block copolymers
US5612052A (en) * 1995-04-13 1997-03-18 Poly-Med, Inc. Hydrogel-forming, self-solvating absorbable polyester copolymers, and methods for use thereof

Also Published As

Publication number Publication date
EP0939639A4 (en) 2002-03-13
WO1998002171A1 (en) 1998-01-22
CA2259603C (en) 2011-02-08
AU735698B2 (en) 2001-07-12
US6136333A (en) 2000-10-24
ES2262182T3 (en) 2006-11-16
ATE330618T1 (en) 2006-07-15
EP0939639B1 (en) 2006-06-21
EP0939639A1 (en) 1999-09-08
DE69736186D1 (en) 2006-08-03
KR20000023724A (en) 2000-04-25
BR9710243A (en) 2000-01-11
US5711958A (en) 1998-01-27
DE69736186T2 (en) 2007-05-03
JP2000514457A (en) 2000-10-31
AU3798497A (en) 1998-02-09

Similar Documents

Publication Publication Date Title
CA2259603A1 (en) Use of polymeric compositions for reducing or eliminating post-surgical adhesion formation
US7879356B2 (en) Polymeric compositions
US8674033B2 (en) Biodegradable phase separated segmented multi block co-polymers
US20070116666A1 (en) Methods and compositions for reducing or eliminating post-surgical adhesion formation
EP1141079B1 (en) Biodegradable low molecular weight triblock polyester polyethylene glycol copolymers having reverse thermal gelation properties
US8674032B2 (en) Biodegradable multi-block co-polymers
EP2629762B1 (en) Pendant hydrophile bearing biodegradable compositions and related devices
JP2001517603A (en) Injectable biodegradable block copolymer gel for use in drug delivery
JP3408349B2 (en) Plasticizer for biodegradable polymer

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed

Effective date: 20160711